Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWTLR agonist 2 is a toll-like receptor 7 (TLR7) agonist with a lowest effective concentration (LEC) value of 0.4 μM in a cell-based reporter assay.1 It is selective for TLR7 over TLR8 (LEC = >100 μM). TLR7 agonist 2 (0.3-10 mg/kg) increases IFN-α levels and the IFN-stimulated gene (ISG) response, increasing the expression of Oas1b, Isg15, and Mx1, in mouse liver and plasma. It increases plasma levels of IFN-α, CCL2, IL-6, IL-1Ra, G-CSF, and IL-10 in cynomolgus monkeys when administered at a dose of 10 mg/kg. TLR agonist 2 (0.3-5 mg/kg) reduces serum and liver viral load in the hydrodynamic injection (HDI) hepatitis B virus (HBV) mouse model.
WARNING This product is not for human or veterinary use.
1. Identification and optimization of pyrrolo[3,2-